Ildong Pharmaceutical Completes Phase 2/3 Clinical Trial of Oral COVID-19 Treatment Zocova
[Asia Economy Reporter Lee Gwan-joo] Ildong Pharmaceutical announced on the 26th that the Phase 2/3 clinical trial of the oral COVID-19 treatment 'Zokova (S-217622)', jointly developed with Japan's Shionogi Pharmaceutical, has been completed.
Following the completion of the final subject observation on the 14th of this month, Ildong Pharmaceutical submitted the clinical trial completion report to the Ministry of Food and Drug Safety on the same day. This clinical trial, which began in November last year, involved a total of approximately 2,900 participants with asymptomatic, mild, and moderate symptoms, of which 204 were domestic subjects.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Report] "I Think Twice Before Going to a Store"... Starbucks '5/18 Tank Day' Controversy Grows
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The topline results are expected to be released next month. Zokova is an oral COVID-19 treatment candidate that works by inhibiting a specific protein-degrading enzyme of the COVID-19 virus, thereby preventing the virus from replicating.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
